Fractyl Health, Inc. (GUTS)
Nasdaq: GUTS · Surgical & Medical Instruments & Apparatus · Burlington, MA · filing with the SEC since 2013
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
| Report filed | Mar 24, 2026 | Mar 3, 2025 | Apr 1, 2024 |
| Revenue | 0 | 93 | 120 |
| Cost of revenue | 0 | 50 | 77 |
| Gross profit | · | 43 | 43 |
| Research and development | 74,536 | 70,471 | 38,038 |
| Selling, general and administrative | 22,280 | 23,103 | 12,841 |
| Total operating expenses | 96,816 | 93,574 | 50,879 |
| Operating income | -96,816 | -93,531 | -50,836 |
| Interest and investment income | 1,540 | 4,146 | 1,260 |
| Other income (expense), net | -53 | -47 | -24 |
| Total non-operating income (expense) | -44,138 | 24,837 | -26,255 |
| Income tax expense | 0 | 0 | 0 |
| Net income including non-controlling interests | -140,954 | -68,694 | -77,091 |
| Net income | -140,954 | -68,694 | -77,091 |
| Net income to common shareholders | -140,954 | -70,431 | -94,271 |
| Earnings per share, basic | -1.86 | -1.62 | -45.29 |
| Earnings per share, diluted | -1.86 | -1.62 | -45.29 |
| Weighted average shares, basic | 75,819,960 | 43,541,527 | 2,081,328 |
| Weighted average shares, diluted | 75,819,960 | 43,541,527 | 2,081,328 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTaxCost of revenue what it cost to make or buy what it sold
us-gaap:CostOfRevenueGross profit revenue less the cost of what it sold
us-gaap:GrossProfitResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseSelling, general and administrative the cost of selling and of running the company
us-gaap:SellingGeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income including non-controlling interests the whole group's profit, minority holders' share included
us-gaap:ProfitLossNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossNet income to common shareholders what is left for common shareholders
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasicEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding